Live federal data · NADAC weekly · Part D CY24

Clonidine Dexmedetomidine

Clonidine vs Dexmedetomidine — $124.0M of combined CY2024 Part D plan spend across 2 molecules. Side-by-side data, every number traced to its CMS or FDA source.

Last updated
NADAC: refreshed weeklyPart D Formulary: quarterlyPart D Spend: annual (CY24)Orange Book: weeklyShortages: daily

Pick the drugs you want to compare.

Up to 4 drugsCross-class or same-class

Start with the molecules your plan spends the most on. Most useful comparisons live within the same therapeutic class — switching across classes requires deeper clinical review.

Drug 1
Drug 2
Drug 3 (optional)
Drug 4 (optional)

Side by side, line by line.

Federal data onlyNo PBM pricing assumed
Compare across
11 dimensions
Central alpha-2 Adrenergic Agonist
Clonidine
Brand: Duraclon
First FDA approval:
Central alpha-2 Adrenergic Agonist
Dexmedetomidine
Brand: Dexmedetomidine Hydrochloride in Sodium Chloride
First FDA approval:
Lowest NADACAcquisition cost floor across all NDCs
$0.025Per unit
—Per unit
Average NADACAcross all dosage forms and strengths
$2.30Up to $15.14
—
Generic manufacturersActive ANDA holders — FDA Orange Book
2351 total ANDAs filed
2449 total ANDAs filed
Annualized Part D spendCY2024 — CMS Part D Spending Dashboard
$123.7MFull year
$308999Full year
Part D claims (CY24)Total fills, all strengths
6.0M1.8M beneficiaries
9742 beneficiaries
Avg cost per claimCalculated: total spend ÷ total claims
$21Per claim, all NDCs
$3,186Per claim, all NDCs
Part D plans surveyed2026 plan year — CMS Formulary file
329Across CMS plan year
329Across CMS plan year
Prior-authorization frictionPlan-NDC pairs requiring PA
6Minimal friction
—Zero PA friction
Step therapy appliedPlan-NDC pairs requiring step therapy
0None
—None
FDA shortage statusLive cross-reference vs FDA Drug Shortage Database
NoneClear
Active shortageSee drug profile
Generic availableFDA Orange Book
Yes23 manufacturers
Yes24 manufacturers